Plasma GFAP associates with secondary Alzheimer's pathology in Lewy body disease

Plasma GFAP associates with secondary Alzheimer's pathology in Lewy body disease

Abstract Objective Within Lewy body spectrum disorders (LBSD) with α‐synuclein pathology (αSyn), concomitant Alzheimer's disease (AD) pathology is common and is predictive of clinical outcomes, including cognitive impairment and decline. Plasma phosphorylated tau 181 (p‐tau181) is sensitive to...

Full description

Bibliographic Details
Main Authors:	Katheryn A. Q. Cousins, David J. Irwin, Alice Chen‐Plotkin, Leslie M. Shaw, Sanaz Arezoumandan, Edward B. Lee, David A. Wolk, Daniel Weintraub, Meredith Spindler, Andres Deik, Murray Grossman, Thomas F. Tropea
Format:	Article
Language:	English
Published:	Wiley 2023-05-01
Series:	Annals of Clinical and Translational Neurology
Online Access:	https://doi.org/10.1002/acn3.51768

Similar Items

Tau maturation in the clinicopathological spectrum of Lewy body and Alzheimer's disease
by: Sanaz Arezoumandan, et al.
Published: (2024-03-01)

Greater white matter degeneration and lower structural connectivity in non-amnestic vs. amnestic Alzheimer’s disease
by: Jeffrey S. Phillips, et al.
Published: (2024-03-01)

CSF proteome profiling reveals biomarkers to discriminate dementia with Lewy bodies from Alzheimer´s disease
by: Marta del Campo, et al.
Published: (2023-09-01)

Plasma phosphorylated tau181 predicts cognitive and functional decline
by: Thomas F. Tropea, et al.
Published: (2023-01-01)

Clinical Correlates of Alzheimer's Disease Cerebrospinal Fluid Analytes in Primary Progressive Aphasia
by: Catherine Norise, et al.
Published: (2019-05-01)

GFAP at 50
by: Albee Messing, et al.
Published: (2020-08-01)

Lateralized ante mortem and post mortem pathology in a case of Lewy body disease with corticobasal syndrome
by: David G. Coughlin, et al.
Published: (2022-01-01)

Astrogliosis instigated signature in neurodegenerative diseases: Supremacy of GFAP in forecasting structural pathology and disease progression in Alzheimer’s disease
by: Sri Harsha Kanuri, et al.
Published: (2024-07-01)

Cognitive decline profiles associated with lewy pathology in the context of Alzheimer’s disease neuropathologic change
by: Jon B. Toledo, et al.
Published: (2024-12-01)

Regulation of GFAP Expression
by: Michael Brenner, et al.
Published: (2021-02-01)

Anosmia in dementia is associated with Lewy bodies rather than Alzheimer's pathology.
by: McShane, R, et al.
Published: (2001)

Neuroinflammation is associated with Alzheimer’s disease co-pathology in dementia with Lewy bodies
by: Janna van Wetering, et al.
Published: (2024-05-01)

GFAP as a Potential Biomarker for Alzheimer’s Disease: A Systematic Review and Meta-Analysis
by: Ka Young Kim, et al.
Published: (2023-05-01)

The Effect of Silybum marianum on GFAP and Spatial Memory in a Mouse Model of Alzheimer\'s Disease
by: A Hadinia, et al.
Published: (2010-01-01)

CSF markers of neurodegeneration Alzheimer’s and Lewy body pathology in isolated REM sleep behavior disorder
by: Amaia Muñoz-Lopetegi, et al.
Published: (2024-08-01)

Network proteomics of the Lewy body dementia brain reveals presynaptic signatures distinct from Alzheimer’s disease
by: Anantharaman Shantaraman, et al.
Published: (2024-08-01)

Lewy- and Alzheimer-type pathologies in Parkinson's disease dementia: which is more important?
by: Compta, Y, et al.
Published: (2011)

Lewy body pathology exacerbates brain hypometabolism and cognitive decline in Alzheimer’s disease
by: Lyduine E. Collij, et al.
Published: (2024-09-01)

Correction: Network proteomics of the Lewy body dementia brain reveals presynaptic signatures distinct from Alzheimer’s disease
by: Anantharaman Shantaraman, et al.
Published: (2024-10-01)

Tracking reactive astrogliosis in autosomal dominant and sporadic Alzheimer’s disease with multi-modal PET and plasma GFAP
by: Konstantinos Chiotis, et al.
Published: (2023-09-01)

Association of Alzheimer’s and Lewy body disease pathology with basal forebrain volume and cognitive impairment
by: Julia Schumacher, et al.
Published: (2025-01-01)

Clinico‐pathological comparison of patients with autopsy‐confirmed Alzheimer's disease, dementia with Lewy bodies, and mixed pathology
by: Atri Chatterjee, et al.
Published: (2021-01-01)

Serological biomarkers in autoimmune GFAP astrocytopathy
by: Cong-Cong Fu, et al.
Published: (2022-08-01)

Tacrine for senile dementia of Alzheimer's or Lewy body type.
by: Wilcock, G, et al.
Published: (1994)

Metabolic brain pattern in dementia with Lewy bodies: Relationship to Alzheimer’s disease topography
by: Matej Perovnik, et al.
Published: (2022-01-01)

APOE-ε4 and BIN1 increase risk of Alzheimer’s disease pathology but not specifically of Lewy body pathology
by: Seth Talyansky, et al.
Published: (2023-09-01)

Cerebrospinal Fluid Biomarkers for Differentiation of Frontotemporal Lobar Degeneration from Alzheimer’s Disease
by: David J Irwin, et al.
Published: (2013-02-01)

Immunofluorescence of GFAP and TNF-α in the Mouse Hypothalamus
by: Prasad Dalvi, et al.
Published: (2021-07-01)

Relapsing Autoimmune GFAP Astrocytopathy: Case Report
by: Ekaterina O. Chekanova, et al.
Published: (2023-12-01)

Asymmetric Distribution of GFAP in Glioma Multipotent Cells.
by: Pierre-Olivier Guichet, et al.
Published: (2016-01-01)

Comparison of category and letter fluency tasks through automated analysis
by: Carmen Gonzalez-Recober, et al.
Published: (2023-10-01)

Longitudinal naming and repetition relates to AD pathology and burden in autopsy‐confirmed primary progressive aphasia
by: Katheryn A.Q. Cousins, et al.
Published: (2021-01-01)

CSF IL-6, GDF-15, GFAP and NfL levels in early Alzheimer disease: a pilot study
by: Domenico Plantone, et al.
Published: (2025-02-01)

GFAP isoforms in adult mouse brain with a focus on neurogenic astrocytes and reactive astrogliosis in mouse models of Alzheimer disease.
by: Willem Kamphuis, et al.
Published: (2012-01-01)

A systematic review and meta-analysis of GFAP gene variants in Alexander disease
by: Alice Grossi, et al.
Published: (2024-10-01)

GFAPβ and GFAPδ Isoforms Expression in Mesenchymal Stem Cells, MSCs Differentiated Towards Schwann-like, and Olfactory Ensheathing Cells
by: Nidia Jannette Carrillo González, et al.
Published: (2025-01-01)

STAT3 Drives GFAP Accumulation and Astrocyte Pathology in a Mouse Model of Alexander Disease
by: Tracy L. Hagemann, et al.
Published: (2023-03-01)

Large-scale gene expression changes in APP/PSEN1 and GFAP mutation models exhibit high congruence with Alzheimer's disease.
by: Stephen C Gammie, et al.
Published: (2024-01-01)

Large-scale gene expression changes in APP/PSEN1 and GFAP mutation models exhibit high congruence with Alzheimer’s disease
by: Stephen C. Gammie, et al.
Published: (2024-01-01)

Trajectories of CSF and plasma biomarkers across Alzheimer's disease continuum: disease staging by NF-L, p-tau181, and GFAP
by: Anna Lidia Wojdała, et al.
Published: (2023-12-01)